Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Publication
, Journal Article
Bramlette, TB; Lawson, DH; Washington, CV; Veledar, E; Johns, BR; Brisman, SF; Abramova, L; Chen, SC
Published in: Dermatol Surg
January 2007
BACKGROUND: Patients with thick (Breslow>4 mm) primary melanoma and/or regional nodal metastasis have a high risk of tumor recurrence. High-dose adjuvant interferon (IFN) alfa-2b offers
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Dermatol Surg
DOI
ISSN
1076-0512
Publication Date
January 2007
Volume
33
Issue
1
Start / End Page
11 / 16
Location
United States
Related Subject Headings
- Skin Neoplasms
- Sentinel Lymph Node Biopsy
- Recombinant Proteins
- Patient Acceptance of Health Care
- Middle Aged
- Melanoma
- Male
- Interferon-alpha
- Interferon alpha-2
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Bramlette, T. B., Lawson, D. H., Washington, C. V., Veledar, E., Johns, B. R., Brisman, S. F., … Chen, S. C. (2007). Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg, 33(1), 11–16. https://doi.org/10.1111/j.1524-4725.2007.33001.x
Bramlette, Tracy B., David H. Lawson, Carl V. Washington, Emir Veledar, Barry R. Johns, Stacey F. Brisman, Liana Abramova, and Suephy C. Chen. “Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.” Dermatol Surg 33, no. 1 (January 2007): 11–16. https://doi.org/10.1111/j.1524-4725.2007.33001.x.
Bramlette TB, Lawson DH, Washington CV, Veledar E, Johns BR, Brisman SF, et al. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg. 2007 Jan;33(1):11–6.
Bramlette, Tracy B., et al. “Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.” Dermatol Surg, vol. 33, no. 1, Jan. 2007, pp. 11–16. Pubmed, doi:10.1111/j.1524-4725.2007.33001.x.
Bramlette TB, Lawson DH, Washington CV, Veledar E, Johns BR, Brisman SF, Abramova L, Chen SC. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg. 2007 Jan;33(1):11–16.
Published In
Dermatol Surg
DOI
ISSN
1076-0512
Publication Date
January 2007
Volume
33
Issue
1
Start / End Page
11 / 16
Location
United States
Related Subject Headings
- Skin Neoplasms
- Sentinel Lymph Node Biopsy
- Recombinant Proteins
- Patient Acceptance of Health Care
- Middle Aged
- Melanoma
- Male
- Interferon-alpha
- Interferon alpha-2
- Humans